UA109265C2 - Застосування перепрограмованих стовбурових нервових клітин в приготуванні медикаменту або фармацевтичної композиції - Google Patents

Info

Publication number

UA109265C2

UA109265C2 UAA201205968A UAA201205968A UA109265C2 UA 109265 C2 UA109265 C2 UA 109265C2 UA A201205968 A UAA201205968 A UA A201205968A UA A201205968 A UAA201205968 A UA A201205968A UA 109265 C2 UA109265 C2 UA 109265C2

Authority

UA

Ukraine

Prior art keywords

cells

application according

sho

shi

cell

Prior art date

2009-10-19

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 title claims abstract description 21
• 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 16
• 238000002360 preparation method Methods 0.000 title claims abstract description 4
• 210000000130 stem cell Anatomy 0.000 title claims description 117
• 230000000474 nursing effect Effects 0.000 title 1
• 210000004027 cell Anatomy 0.000 claims abstract description 599
• 230000008672 reprogramming Effects 0.000 claims abstract description 44
• 239000000427 antigen Substances 0.000 claims abstract description 19
• 108091007433 antigens Proteins 0.000 claims abstract description 19
• 102000036639 antigens Human genes 0.000 claims abstract description 19
• 208000012902 Nervous system disease Diseases 0.000 claims abstract description 3
• 208000025966 Neurological disease Diseases 0.000 claims abstract description 3
• 238000001802 infusion Methods 0.000 claims description 111
• 238000011282 treatment Methods 0.000 claims description 96
• 238000000034 method Methods 0.000 claims description 77
• 210000004369 blood Anatomy 0.000 claims description 59
• 239000008280 blood Substances 0.000 claims description 59
• 239000003795 chemical substances by application Substances 0.000 claims description 55
• 210000001519 tissue Anatomy 0.000 claims description 47
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 46
• 102000005962 receptors Human genes 0.000 claims description 45
• 108020003175 receptors Proteins 0.000 claims description 45
• 201000010099 disease Diseases 0.000 claims description 36
• JYGXADMDTFJGBT-VWUMJDOOSA-N Hydrocortisone Natural products O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 35
• 210000000265 leukocyte Anatomy 0.000 claims description 32
• 102000001554 Hemoglobins Human genes 0.000 claims description 30
• 108010054147 Hemoglobins Proteins 0.000 claims description 30
• 230000004069 differentiation Effects 0.000 claims description 30
• 210000003743 erythrocyte Anatomy 0.000 claims description 30
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 24
• 210000001185 bone marrow Anatomy 0.000 claims description 24
• 206010012601 diabetes mellitus Diseases 0.000 claims description 23
• 210000004185 liver Anatomy 0.000 claims description 23
• 210000002966 serum Anatomy 0.000 claims description 21
• 239000002609 medium Substances 0.000 claims description 20
• 210000001772 blood platelet Anatomy 0.000 claims description 19
• 229960000890 hydrocortisone Drugs 0.000 claims description 18
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 17
• 229960003957 dexamethasone Drugs 0.000 claims description 17
• 229940079593 drug Drugs 0.000 claims description 16
• 229940088594 vitamin Drugs 0.000 claims description 15
• 229930003231 vitamin Natural products 0.000 claims description 15
• 239000011782 vitamin Substances 0.000 claims description 15
• 102000004190 Enzymes Human genes 0.000 claims description 14
• 108090000790 Enzymes Proteins 0.000 claims description 14
• 210000003205 muscle Anatomy 0.000 claims description 14
• 108090000623 proteins and genes Proteins 0.000 claims description 14
• 210000003491 skin Anatomy 0.000 claims description 14
• 235000013343 vitamin Nutrition 0.000 claims description 14
• 239000001963 growth medium Substances 0.000 claims description 13
• 210000004698 lymphocyte Anatomy 0.000 claims description 13
• 210000001744 T-lymphocyte Anatomy 0.000 claims description 12
• 208000017169 kidney disease Diseases 0.000 claims description 12
• 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 11
• 238000002617 apheresis Methods 0.000 claims description 11
• 238000002347 injection Methods 0.000 claims description 11
• 239000007924 injection Substances 0.000 claims description 11
• 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 11
• 150000003722 vitamin derivatives Chemical class 0.000 claims description 11
• 206010019196 Head injury Diseases 0.000 claims description 10
• 235000010323 ascorbic acid Nutrition 0.000 claims description 10
• 239000011668 ascorbic acid Substances 0.000 claims description 10
• 208000035475 disorder Diseases 0.000 claims description 10
• 201000006417 multiple sclerosis Diseases 0.000 claims description 10
• 210000001178 neural stem cell Anatomy 0.000 claims description 10
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
• 208000018737 Parkinson disease Diseases 0.000 claims description 9
• 239000003242 anti bacterial agent Substances 0.000 claims description 9
• 238000012258 culturing Methods 0.000 claims description 9
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 8
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 8
• 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
• 239000002738 chelating agent Substances 0.000 claims description 8
• CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 8
• 210000001616 monocyte Anatomy 0.000 claims description 8
• 208000005264 motor neuron disease Diseases 0.000 claims description 8
• 210000000440 neutrophil Anatomy 0.000 claims description 8
• 102000004169 proteins and genes Human genes 0.000 claims description 8
• KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 claims description 8
• 239000003104 tissue culture media Substances 0.000 claims description 8
• 229930024421 Adenine Natural products 0.000 claims description 7
• GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 7
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 7
• SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims description 7
• 229960000643 adenine Drugs 0.000 claims description 7
• 239000003146 anticoagulant agent Substances 0.000 claims description 7
• 229940127219 anticoagulant drug Drugs 0.000 claims description 7
• 230000003115 biocidal effect Effects 0.000 claims description 7
• 150000001875 compounds Chemical class 0.000 claims description 7
• 210000003714 granulocyte Anatomy 0.000 claims description 7
• 210000003593 megakaryocyte Anatomy 0.000 claims description 7
• 239000001301 oxygen Substances 0.000 claims description 7
• 229910052760 oxygen Inorganic materials 0.000 claims description 7
• 229930002330 retinoic acid Natural products 0.000 claims description 7
• 239000011734 sodium Substances 0.000 claims description 7
• 208000020431 spinal cord injury Diseases 0.000 claims description 7
• 229960001727 tretinoin Drugs 0.000 claims description 7
• OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims description 6
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims description 6
• 229930182566 Gentamicin Natural products 0.000 claims description 6
• 208000026072 Motor neurone disease Diseases 0.000 claims description 6
• 150000001413 amino acids Chemical class 0.000 claims description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
• 229960002518 gentamicin Drugs 0.000 claims description 6
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 claims description 6
• 239000004033 plastic Substances 0.000 claims description 6
• 229920003023 plastic Polymers 0.000 claims description 6
• FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 5
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 5
• 210000003651 basophil Anatomy 0.000 claims description 5
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 4
• 102000004420 Creatine Kinase Human genes 0.000 claims description 4
• 108010042126 Creatine kinase Proteins 0.000 claims description 4
• 108010010803 Gelatin Proteins 0.000 claims description 4
• 102000003855 L-lactate dehydrogenase Human genes 0.000 claims description 4
• 108700023483 L-lactate dehydrogenases Proteins 0.000 claims description 4
• BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 4
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
• 239000005700 Putrescine Substances 0.000 claims description 4
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims description 4
• 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 4
• 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 4
• 239000002253 acid Substances 0.000 claims description 4
• 229960005070 ascorbic acid Drugs 0.000 claims description 4
• 229960002756 azacitidine Drugs 0.000 claims description 4
• 239000011575 calcium Substances 0.000 claims description 4
• 229910052791 calcium Inorganic materials 0.000 claims description 4
• 239000001569 carbon dioxide Substances 0.000 claims description 4
• 229910002092 carbon dioxide Inorganic materials 0.000 claims description 4
• 210000003979 eosinophil Anatomy 0.000 claims description 4
• 230000004438 eyesight Effects 0.000 claims description 4
• 239000012530 fluid Substances 0.000 claims description 4
• 229920000159 gelatin Polymers 0.000 claims description 4
• 239000008273 gelatin Substances 0.000 claims description 4
• 235000019322 gelatine Nutrition 0.000 claims description 4
• 235000011852 gelatine desserts Nutrition 0.000 claims description 4
• 229960000905 indomethacin Drugs 0.000 claims description 4
• 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
• 239000011707 mineral Substances 0.000 claims description 4
• 239000002777 nucleoside Substances 0.000 claims description 4
• 229940124531 pharmaceutical excipient Drugs 0.000 claims description 4
• 229960000187 tissue plasminogen activator Drugs 0.000 claims description 4
• 239000011701 zinc Substances 0.000 claims description 4
• 229910052725 zinc Inorganic materials 0.000 claims description 4
• FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims description 3
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical group O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims description 3
• 108010035532 Collagen Proteins 0.000 claims description 3
• 102000008186 Collagen Human genes 0.000 claims description 3
• SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims description 3
• QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 3
• 102000008857 Ferritin Human genes 0.000 claims description 3
• 108050000784 Ferritin Proteins 0.000 claims description 3
• 238000008416 Ferritin Methods 0.000 claims description 3
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 claims description 3
• UIAYVIIHMORPSJ-UHFFFAOYSA-N N-cyclohexyl-N-methyl-4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide Chemical compound C=1C=C2NC(=O)C=CC2=CC=1OCCCC(=O)N(C)C1CCCCC1 UIAYVIIHMORPSJ-UHFFFAOYSA-N 0.000 claims description 3
• DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
• AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
• 229960005069 calcium Drugs 0.000 claims description 3
• 229940043430 calcium compound Drugs 0.000 claims description 3
• 150000001674 calcium compounds Chemical class 0.000 claims description 3
• 229950002934 cilostamide Drugs 0.000 claims description 3
• OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims description 3
• 229920001436 collagen Polymers 0.000 claims description 3
• 239000003688 hormone derivative Substances 0.000 claims description 3
• 238000002513 implantation Methods 0.000 claims description 3
• 230000001537 neural effect Effects 0.000 claims description 3
• 150000003833 nucleoside derivatives Chemical class 0.000 claims description 3
• 229960001476 pentoxifylline Drugs 0.000 claims description 3
• 150000003839 salts Chemical class 0.000 claims description 3
• AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 claims description 3
• MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims description 3
• 238000009168 stem cell therapy Methods 0.000 claims description 3
• 238000009580 stem-cell therapy Methods 0.000 claims description 3
• OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 claims description 2
• APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 claims description 2
• VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 claims description 2
• 108010075254 C-Peptide Proteins 0.000 claims description 2
• ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
• 229930003268 Vitamin C Natural products 0.000 claims description 2
• 229930003448 Vitamin K Natural products 0.000 claims description 2
• 150000007513 acids Chemical class 0.000 claims description 2
• 229960001484 edetic acid Drugs 0.000 claims description 2
• 210000002615 epidermis Anatomy 0.000 claims description 2
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 claims description 2
• 210000002744 extracellular matrix Anatomy 0.000 claims description 2
• 210000003630 histaminocyte Anatomy 0.000 claims description 2
• 108010082117 matrigel Proteins 0.000 claims description 2
• PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 claims description 2
• SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
• 235000019154 vitamin C Nutrition 0.000 claims description 2
• 239000011718 vitamin C Substances 0.000 claims description 2
• 235000019168 vitamin K Nutrition 0.000 claims description 2
• 239000011712 vitamin K Substances 0.000 claims description 2
• 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
• 229940046010 vitamin k Drugs 0.000 claims description 2
• 150000003752 zinc compounds Chemical class 0.000 claims description 2
• 244000005894 Albizia lebbeck Species 0.000 claims 3
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
• QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 claims 2
• VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 claims 2
• FBOUIAKEJMZPQG-AWNIVKPZSA-N (1E)-1-(2,4-dichlorophenyl)-4,4-dimethyl-2-(1,2,4-triazol-1-yl)pent-1-en-3-ol Chemical compound C1=NC=NN1/C(C(O)C(C)(C)C)=C/C1=CC=C(Cl)C=C1Cl FBOUIAKEJMZPQG-AWNIVKPZSA-N 0.000 claims 1
• IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 claims 1
• 240000005220 Bischofia javanica Species 0.000 claims 1
• 235000010893 Bischofia javanica Nutrition 0.000 claims 1
• 241000224511 Bodo Species 0.000 claims 1
• 241000566113 Branta sandvicensis Species 0.000 claims 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
• 229920000742 Cotton Polymers 0.000 claims 1
• 244000241257 Cucumis melo Species 0.000 claims 1
• 235000015510 Cucumis melo subsp melo Nutrition 0.000 claims 1
• YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 claims 1
• 206010012735 Diarrhoea Diseases 0.000 claims 1
• JYFHYPJRHGVZDY-UHFFFAOYSA-N Dibutyl phosphate Chemical compound CCCCOP(O)(=O)OCCCC JYFHYPJRHGVZDY-UHFFFAOYSA-N 0.000 claims 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 1
• 244000301682 Heliotropium curassavicum Species 0.000 claims 1
• 235000015854 Heliotropium curassavicum Nutrition 0.000 claims 1
• 241000824268 Kuma Species 0.000 claims 1
• SSISHJJTAXXQAX-ZETCQYMHSA-N L-ergothioneine Chemical compound C[N+](C)(C)[C@H](C([O-])=O)CC1=CNC(=S)N1 SSISHJJTAXXQAX-ZETCQYMHSA-N 0.000 claims 1
• 241001214257 Mene Species 0.000 claims 1
• 206010027525 Microalbuminuria Diseases 0.000 claims 1
• 208000007256 Nevus Diseases 0.000 claims 1
• 241000514450 Podocarpus latifolius Species 0.000 claims 1
• 241001233278 Scalopus aquaticus Species 0.000 claims 1
• 241001415849 Strigiformes Species 0.000 claims 1
• FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims 1
• FJJCIZWZNKZHII-UHFFFAOYSA-N [4,6-bis(cyanoamino)-1,3,5-triazin-2-yl]cyanamide Chemical compound N#CNC1=NC(NC#N)=NC(NC#N)=N1 FJJCIZWZNKZHII-UHFFFAOYSA-N 0.000 claims 1
• 239000008186 active pharmaceutical agent Substances 0.000 claims 1
• 229960005305 adenosine Drugs 0.000 claims 1
• 235000013351 cheese Nutrition 0.000 claims 1
• 239000003984 copper intrauterine device Substances 0.000 claims 1
• 125000000017 cortisol group Chemical group 0.000 claims 1
• 125000004122 cyclic group Chemical group 0.000 claims 1
• 230000006866 deterioration Effects 0.000 claims 1
• 229940093497 ergothioneine Drugs 0.000 claims 1
• 235000013305 food Nutrition 0.000 claims 1
• 230000035929 gnawing Effects 0.000 claims 1
• 230000035939 shock Effects 0.000 claims 1
• 239000004334 sorbic acid Substances 0.000 claims 1
• 239000000758 substrate Substances 0.000 claims 1
• ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims 1
• 239000011719 vitamin A Substances 0.000 claims 1
• 235000019155 vitamin A Nutrition 0.000 claims 1
• 229940045997 vitamin a Drugs 0.000 claims 1
• 229940100888 zinc compound Drugs 0.000 claims 1
• 210000002569 neuron Anatomy 0.000 abstract description 30
• 210000001778 pluripotent stem cell Anatomy 0.000 description 38
• 230000006378 damage Effects 0.000 description 30
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 25
• 208000032467 Aplastic anaemia Diseases 0.000 description 24
• 210000004731 jugular vein Anatomy 0.000 description 19
• 230000006872 improvement Effects 0.000 description 18
• 230000009467 reduction Effects 0.000 description 17
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 16
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 16
• DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 16
• 238000000684 flow cytometry Methods 0.000 description 16
• 210000004556 brain Anatomy 0.000 description 15
• 239000008103 glucose Substances 0.000 description 15
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 15
• 208000002903 Thalassemia Diseases 0.000 description 14
• 230000002829 reductive effect Effects 0.000 description 14
• 238000002560 therapeutic procedure Methods 0.000 description 14
• 230000007423 decrease Effects 0.000 description 13
• 230000000694 effects Effects 0.000 description 13
• 210000002901 mesenchymal stem cell Anatomy 0.000 description 13
• 108010001857 Cell Surface Receptors Proteins 0.000 description 12
• 102000000844 Cell Surface Receptors Human genes 0.000 description 12
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
• 230000003394 haemopoietic effect Effects 0.000 description 12
• 230000003907 kidney function Effects 0.000 description 11
• 238000012545 processing Methods 0.000 description 11
• 108010082126 Alanine transaminase Proteins 0.000 description 10
• 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 10
• 102100037852 Insulin-like growth factor I Human genes 0.000 description 10
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 10
• 208000007502 anemia Diseases 0.000 description 10
• 230000014509 gene expression Effects 0.000 description 10
• 239000003102 growth factor Substances 0.000 description 10
• 238000001990 intravenous administration Methods 0.000 description 10
• 239000000463 material Substances 0.000 description 10
• 210000000287 oocyte Anatomy 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 210000000689 upper leg Anatomy 0.000 description 10
• 201000004569 Blindness Diseases 0.000 description 9
• 241000711549 Hepacivirus C Species 0.000 description 9
• 208000019693 Lung disease Diseases 0.000 description 9
• 108090000340 Transaminases Proteins 0.000 description 9
• 230000027455 binding Effects 0.000 description 9
• 208000019425 cirrhosis of liver Diseases 0.000 description 9
• VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 9
• 210000004072 lung Anatomy 0.000 description 9
• 210000000278 spinal cord Anatomy 0.000 description 9
• 102000014898 transaminase activity proteins Human genes 0.000 description 9
• 210000002798 bone marrow cell Anatomy 0.000 description 8
• 229940109239 creatinine Drugs 0.000 description 8
• 230000007774 longterm Effects 0.000 description 8
• 238000002595 magnetic resonance imaging Methods 0.000 description 8
• 239000000203 mixture Substances 0.000 description 8
• 201000006938 muscular dystrophy Diseases 0.000 description 8
• 210000005259 peripheral blood Anatomy 0.000 description 8
• 239000011886 peripheral blood Substances 0.000 description 8
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 8
• 208000024891 symptom Diseases 0.000 description 8
• 238000012360 testing method Methods 0.000 description 8
• 206010007559 Cardiac failure congestive Diseases 0.000 description 7
• 108010014663 Glycated Hemoglobin A Proteins 0.000 description 7
• 102000017011 Glycated Hemoglobin A Human genes 0.000 description 7
• 206010019280 Heart failures Diseases 0.000 description 7
• 241000725303 Human immunodeficiency virus Species 0.000 description 7
• 102000004877 Insulin Human genes 0.000 description 7
• 108090001061 Insulin Proteins 0.000 description 7
• 210000001789 adipocyte Anatomy 0.000 description 7
• 238000004458 analytical method Methods 0.000 description 7
• 208000005980 beta thalassemia Diseases 0.000 description 7
• 239000004202 carbamide Substances 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 210000002889 endothelial cell Anatomy 0.000 description 7
• 210000004602 germ cell Anatomy 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 229940125396 insulin Drugs 0.000 description 7
• 210000004153 islets of langerhan Anatomy 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 230000004393 visual impairment Effects 0.000 description 7
• 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
• BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 6
• 102000043129 MHC class I family Human genes 0.000 description 6
• 108091054437 MHC class I family Proteins 0.000 description 6
• 210000002821 alveolar epithelial cell Anatomy 0.000 description 6
• 206010003883 azoospermia Diseases 0.000 description 6
• 238000004159 blood analysis Methods 0.000 description 6
• 230000023555 blood coagulation Effects 0.000 description 6
• 210000004413 cardiac myocyte Anatomy 0.000 description 6
• 210000001671 embryonic stem cell Anatomy 0.000 description 6
• 238000005516 engineering process Methods 0.000 description 6
• 210000003494 hepatocyte Anatomy 0.000 description 6
• 210000005087 mononuclear cell Anatomy 0.000 description 6
• 239000002243 precursor Substances 0.000 description 6
• 235000018102 proteins Nutrition 0.000 description 6
• 230000008439 repair process Effects 0.000 description 6
• 230000035945 sensitivity Effects 0.000 description 6
• 102100027211 Albumin Human genes 0.000 description 5
• 108010088751 Albumins Proteins 0.000 description 5
• 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
• 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
• 208000023275 Autoimmune disease Diseases 0.000 description 5
• 101800000407 Brain natriuretic peptide 32 Proteins 0.000 description 5
• 102400000667 Brain natriuretic peptide 32 Human genes 0.000 description 5
• 101800002247 Brain natriuretic peptide 45 Proteins 0.000 description 5
• 108010044495 Fetal Hemoglobin Proteins 0.000 description 5
• 206010016654 Fibrosis Diseases 0.000 description 5
• 208000005176 Hepatitis C Diseases 0.000 description 5
• 206010028980 Neoplasm Diseases 0.000 description 5
• 201000004681 Psoriasis Diseases 0.000 description 5
• 206010039710 Scleroderma Diseases 0.000 description 5
• PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 5
• 229940088710 antibiotic agent Drugs 0.000 description 5
• 229940072107 ascorbate Drugs 0.000 description 5
• 210000003169 central nervous system Anatomy 0.000 description 5
• 210000001612 chondrocyte Anatomy 0.000 description 5
• 208000020832 chronic kidney disease Diseases 0.000 description 5
• 210000004700 fetal blood Anatomy 0.000 description 5
• 230000006870 function Effects 0.000 description 5
• 210000002216 heart Anatomy 0.000 description 5
• 229940088597 hormone Drugs 0.000 description 5
• 239000005556 hormone Substances 0.000 description 5
• 208000014674 injury Diseases 0.000 description 5
• 210000003734 kidney Anatomy 0.000 description 5
• 210000003738 lymphoid progenitor cell Anatomy 0.000 description 5
• 238000002483 medication Methods 0.000 description 5
• 238000010208 microarray analysis Methods 0.000 description 5
• 238000012544 monitoring process Methods 0.000 description 5
• 210000002161 motor neuron Anatomy 0.000 description 5
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 5
• DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 210000002363 skeletal muscle cell Anatomy 0.000 description 5
• -1 stem cell factor Proteins 0.000 description 5
• 230000004083 survival effect Effects 0.000 description 5
• 229960003604 testosterone Drugs 0.000 description 5
• 238000002054 transplantation Methods 0.000 description 5
• 230000003612 virological effect Effects 0.000 description 5
• 208000030507 AIDS Diseases 0.000 description 4
• 208000000059 Dyspnea Diseases 0.000 description 4
• 206010013975 Dyspnoeas Diseases 0.000 description 4
• 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 4
• 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 4
• 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 4
• 208000032843 Hemorrhage Diseases 0.000 description 4
• 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
• 101100187130 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) nim-1 gene Proteins 0.000 description 4
• 108010094028 Prothrombin Proteins 0.000 description 4
• 102100027378 Prothrombin Human genes 0.000 description 4
• 230000015572 biosynthetic process Effects 0.000 description 4
• 230000000740 bleeding effect Effects 0.000 description 4
• 238000004820 blood count Methods 0.000 description 4
• 210000000988 bone and bone Anatomy 0.000 description 4
• 238000004113 cell culture Methods 0.000 description 4
• 238000002659 cell therapy Methods 0.000 description 4
• 230000007882 cirrhosis Effects 0.000 description 4
• 230000001332 colony forming effect Effects 0.000 description 4
• 208000029078 coronary artery disease Diseases 0.000 description 4
• 230000003247 decreasing effect Effects 0.000 description 4
• 230000007850 degeneration Effects 0.000 description 4
• 238000010790 dilution Methods 0.000 description 4
• 239000012895 dilution Substances 0.000 description 4
• 229960003638 dopamine Drugs 0.000 description 4
• 239000003937 drug carrier Substances 0.000 description 4
• 210000002919 epithelial cell Anatomy 0.000 description 4
• 230000000925 erythroid effect Effects 0.000 description 4
• 229940028334 follicle stimulating hormone Drugs 0.000 description 4
• 230000012010 growth Effects 0.000 description 4
• 210000000987 immune system Anatomy 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 210000002510 keratinocyte Anatomy 0.000 description 4
• 210000005240 left ventricle Anatomy 0.000 description 4
• 239000003446 ligand Substances 0.000 description 4
• 239000003550 marker Substances 0.000 description 4
• 210000002752 melanocyte Anatomy 0.000 description 4
• 230000009245 menopause Effects 0.000 description 4
• 230000000414 obstructive effect Effects 0.000 description 4
• 210000004409 osteocyte Anatomy 0.000 description 4
• 230000000704 physical effect Effects 0.000 description 4
• 239000000047 product Substances 0.000 description 4
• 229940039716 prothrombin Drugs 0.000 description 4
• 230000001105 regulatory effect Effects 0.000 description 4
• 230000004044 response Effects 0.000 description 4
• 210000001995 reticulocyte Anatomy 0.000 description 4
• 230000002207 retinal effect Effects 0.000 description 4
• 239000000523 sample Substances 0.000 description 4
• QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
• 208000013220 shortness of breath Diseases 0.000 description 4
• 210000002027 skeletal muscle Anatomy 0.000 description 4
• 229940054269 sodium pyruvate Drugs 0.000 description 4
• 210000002536 stromal cell Anatomy 0.000 description 4
• 230000000451 tissue damage Effects 0.000 description 4
• 231100000827 tissue damage Toxicity 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• 210000002700 urine Anatomy 0.000 description 4
• 230000002861 ventricular Effects 0.000 description 4
• IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
• 101800003838 Epidermal growth factor Proteins 0.000 description 3
• 102000003951 Erythropoietin Human genes 0.000 description 3
• 108090000394 Erythropoietin Proteins 0.000 description 3
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 3
• 208000009329 Graft vs Host Disease Diseases 0.000 description 3
• 108010068323 Hemoglobin E Proteins 0.000 description 3
• 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 3
• 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 3
• 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 3
• 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 3
• 206010020772 Hypertension Diseases 0.000 description 3
• 206010021074 Hypoplastic anaemia Diseases 0.000 description 3
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
• MIJPAVRNWPDMOR-ZAFYKAAXSA-N L-ascorbic acid 2-phosphate Chemical compound OC[C@H](O)[C@H]1OC(=O)C(OP(O)(O)=O)=C1O MIJPAVRNWPDMOR-ZAFYKAAXSA-N 0.000 description 3
• OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
• 102000009151 Luteinizing Hormone Human genes 0.000 description 3
• 108010073521 Luteinizing Hormone Proteins 0.000 description 3
• 102000043131 MHC class II family Human genes 0.000 description 3
• 108091054438 MHC class II family Proteins 0.000 description 3
• 208000008238 Muscle Spasticity Diseases 0.000 description 3
• 108091034117 Oligonucleotide Proteins 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• 108090000445 Parathyroid hormone Proteins 0.000 description 3
• 102000003982 Parathyroid hormone Human genes 0.000 description 3
• 206010038910 Retinitis Diseases 0.000 description 3
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
• 206010043391 Thalassaemia beta Diseases 0.000 description 3
• 208000007536 Thrombosis Diseases 0.000 description 3
• 102000040945 Transcription factor Human genes 0.000 description 3
• 108091023040 Transcription factor Proteins 0.000 description 3
• 206010044565 Tremor Diseases 0.000 description 3
• 208000025865 Ulcer Diseases 0.000 description 3
• LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 3
• TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 3
• 208000027418 Wounds and injury Diseases 0.000 description 3
• JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 230000000735 allogeneic effect Effects 0.000 description 3
• 238000003556 assay Methods 0.000 description 3
• 239000007640 basal medium Substances 0.000 description 3
• 239000011324 bead Substances 0.000 description 3
• 239000012620 biological material Substances 0.000 description 3
• 239000010836 blood and blood product Substances 0.000 description 3
• 229940125691 blood product Drugs 0.000 description 3
• 208000015322 bone marrow disease Diseases 0.000 description 3
• 201000011510 cancer Diseases 0.000 description 3
• 210000000845 cartilage Anatomy 0.000 description 3
• 239000002458 cell surface marker Substances 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• 208000022831 chronic renal failure syndrome Diseases 0.000 description 3
• 239000003246 corticosteroid Substances 0.000 description 3
• 235000005911 diet Nutrition 0.000 description 3
• 230000037213 diet Effects 0.000 description 3
• 239000003085 diluting agent Substances 0.000 description 3
• 210000001705 ectoderm cell Anatomy 0.000 description 3
• 210000004039 endoderm cell Anatomy 0.000 description 3
• 229940116977 epidermal growth factor Drugs 0.000 description 3
• 229940105423 erythropoietin Drugs 0.000 description 3
• 208000024908 graft versus host disease Diseases 0.000 description 3
• 238000005534 hematocrit Methods 0.000 description 3
• 208000010710 hepatitis C virus infection Diseases 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 238000013394 immunophenotyping Methods 0.000 description 3
• 208000000509 infertility Diseases 0.000 description 3
• 230000036512 infertility Effects 0.000 description 3
• 231100000535 infertility Toxicity 0.000 description 3
• 230000000977 initiatory effect Effects 0.000 description 3
• 210000003292 kidney cell Anatomy 0.000 description 3
• 230000003902 lesion Effects 0.000 description 3
• OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 3
• 235000020778 linoleic acid Nutrition 0.000 description 3
• 229940040129 luteinizing hormone Drugs 0.000 description 3
• 239000007758 minimum essential medium Substances 0.000 description 3
• 210000003887 myelocyte Anatomy 0.000 description 3
• 210000004165 myocardium Anatomy 0.000 description 3
• 210000000822 natural killer cell Anatomy 0.000 description 3
• HPNRHPKXQZSDFX-OAQDCNSJSA-N nesiritide Chemical compound C([C@H]1C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CO)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1N=CNC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 HPNRHPKXQZSDFX-OAQDCNSJSA-N 0.000 description 3
• 210000004940 nucleus Anatomy 0.000 description 3
• 239000000199 parathyroid hormone Substances 0.000 description 3
• 229960001319 parathyroid hormone Drugs 0.000 description 3
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
• 238000002203 pretreatment Methods 0.000 description 3
• 230000000750 progressive effect Effects 0.000 description 3
• 201000008752 progressive muscular atrophy Diseases 0.000 description 3
• 238000009613 pulmonary function test Methods 0.000 description 3
• 229940076788 pyruvate Drugs 0.000 description 3
• 230000003716 rejuvenation Effects 0.000 description 3
• 238000000926 separation method Methods 0.000 description 3
• 208000007056 sickle cell anemia Diseases 0.000 description 3
• 208000002320 spinal muscular atrophy Diseases 0.000 description 3
• 238000011476 stem cell transplantation Methods 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 238000001356 surgical procedure Methods 0.000 description 3
• 229940116269 uric acid Drugs 0.000 description 3
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 3
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• 102100023245 Asparagine-tRNA ligase, cytoplasmic Human genes 0.000 description 2
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
• 206010003694 Atrophy Diseases 0.000 description 2
• 208000024806 Brain atrophy Diseases 0.000 description 2
• 229940123150 Chelating agent Drugs 0.000 description 2
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
• 108010036949 Cyclosporine Proteins 0.000 description 2
• XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 102000006395 Globulins Human genes 0.000 description 2
• 108010044091 Globulins Proteins 0.000 description 2
• DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
• 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 108010051696 Growth Hormone Proteins 0.000 description 2
• 206010018852 Haematoma Diseases 0.000 description 2
• 108010085682 Hemoglobin A Proteins 0.000 description 2
• 102000007513 Hemoglobin A Human genes 0.000 description 2
• 108010027616 Hemoglobin A2 Proteins 0.000 description 2
• 101000624939 Homo sapiens Asparagine-tRNA ligase, cytoplasmic Proteins 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 206010065973 Iron Overload Diseases 0.000 description 2
• 102000007330 LDL Lipoproteins Human genes 0.000 description 2
• 108010007622 LDL Lipoproteins Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• 101150076359 Mhc gene Proteins 0.000 description 2
• 208000010428 Muscle Weakness Diseases 0.000 description 2
• 206010028289 Muscle atrophy Diseases 0.000 description 2
• 206010028372 Muscular weakness Diseases 0.000 description 2
• 108010083674 Myelin Proteins Proteins 0.000 description 2
• 102000006386 Myelin Proteins Human genes 0.000 description 2
• DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
• CZWCKYRVOZZJNM-UHFFFAOYSA-N Prasterone sodium sulfate Natural products C1C(OS(O)(=O)=O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 CZWCKYRVOZZJNM-UHFFFAOYSA-N 0.000 description 2
• 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 2
• RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
• 206010037660 Pyrexia Diseases 0.000 description 2
• LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
• 206010040954 Skin wrinkling Diseases 0.000 description 2
• 102100038803 Somatotropin Human genes 0.000 description 2
• AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
• 102000011923 Thyrotropin Human genes 0.000 description 2
• 108010061174 Thyrotropin Proteins 0.000 description 2
• 206010047700 Vomiting Diseases 0.000 description 2
• 239000003470 adrenal cortex hormone Substances 0.000 description 2
• 238000001042 affinity chromatography Methods 0.000 description 2
• 239000002168 alkylating agent Substances 0.000 description 2
• 229940100198 alkylating agent Drugs 0.000 description 2
• 229940024606 amino acid Drugs 0.000 description 2
• 235000001014 amino acid Nutrition 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 230000037444 atrophy Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 201000004995 autoimmune glomerulonephritis Diseases 0.000 description 2
• 210000003050 axon Anatomy 0.000 description 2
• 208000022809 beta-thalassemia intermedia Diseases 0.000 description 2
• 208000022806 beta-thalassemia major Diseases 0.000 description 2
• 239000012472 biological sample Substances 0.000 description 2
• 239000000090 biomarker Substances 0.000 description 2
• 208000034158 bleeding Diseases 0.000 description 2
• 210000000601 blood cell Anatomy 0.000 description 2
• 210000004271 bone marrow stromal cell Anatomy 0.000 description 2
• 210000005013 brain tissue Anatomy 0.000 description 2
• 210000003123 bronchiole Anatomy 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000003833 cell viability Effects 0.000 description 2
• 230000001684 chronic effect Effects 0.000 description 2
• 229960001265 ciclosporin Drugs 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 238000011443 conventional therapy Methods 0.000 description 2
• 229960001334 corticosteroids Drugs 0.000 description 2
• 230000008878 coupling Effects 0.000 description 2
• 238000010168 coupling process Methods 0.000 description 2
• 238000005859 coupling reaction Methods 0.000 description 2
• 229930182912 cyclosporin Natural products 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 230000007547 defect Effects 0.000 description 2
• 210000004207 dermis Anatomy 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 238000003745 diagnosis Methods 0.000 description 2
• 210000005064 dopaminergic neuron Anatomy 0.000 description 2
• 210000001951 dura mater Anatomy 0.000 description 2
• 210000003981 ectoderm Anatomy 0.000 description 2
• 230000002500 effect on skin Effects 0.000 description 2
• 210000002308 embryonic cell Anatomy 0.000 description 2
• 210000002257 embryonic structure Anatomy 0.000 description 2
• 208000028208 end stage renal disease Diseases 0.000 description 2
• 201000000523 end stage renal failure Diseases 0.000 description 2
• 210000001900 endoderm Anatomy 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• 230000002068 genetic effect Effects 0.000 description 2
• 102000018146 globin Human genes 0.000 description 2
• 108060003196 globin Proteins 0.000 description 2
• 239000003163 gonadal steroid hormone Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000005484 gravity Effects 0.000 description 2
• 239000000122 growth hormone Substances 0.000 description 2
• 238000001631 haemodialysis Methods 0.000 description 2
• 230000003676 hair loss Effects 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 230000002489 hematologic effect Effects 0.000 description 2
• 230000000322 hemodialysis Effects 0.000 description 2
• 230000011132 hemopoiesis Effects 0.000 description 2
• 201000001421 hyperglycemia Diseases 0.000 description 2
• 239000000367 immunologic factor Substances 0.000 description 2
• 230000001506 immunosuppresive effect Effects 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000003914 insulin secretion Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000007914 intraventricular administration Methods 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 239000007791 liquid phase Substances 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 208000019423 liver disease Diseases 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 235000012054 meals Nutrition 0.000 description 2
• 229920000609 methyl cellulose Polymers 0.000 description 2
• 239000001923 methylcellulose Substances 0.000 description 2
• 238000002493 microarray Methods 0.000 description 2
• 238000000386 microscopy Methods 0.000 description 2
• 235000010755 mineral Nutrition 0.000 description 2
• 230000020763 muscle atrophy Effects 0.000 description 2
• 201000000585 muscular atrophy Diseases 0.000 description 2
• 210000005012 myelin Anatomy 0.000 description 2
• 210000001577 neostriatum Anatomy 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 208000004235 neutropenia Diseases 0.000 description 2
• 235000005152 nicotinamide Nutrition 0.000 description 2
• 239000011570 nicotinamide Substances 0.000 description 2
• 229960003966 nicotinamide Drugs 0.000 description 2
• 210000001009 nucleus accumben Anatomy 0.000 description 2
• 235000015097 nutrients Nutrition 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 150000002894 organic compounds Chemical class 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 210000001696 pelvic girdle Anatomy 0.000 description 2
• 210000001428 peripheral nervous system Anatomy 0.000 description 2
• 229910052698 phosphorus Inorganic materials 0.000 description 2
• 239000011574 phosphorus Substances 0.000 description 2
• 238000000554 physical therapy Methods 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 210000003281 pleural cavity Anatomy 0.000 description 2
• 229950009829 prasterone sulfate Drugs 0.000 description 2
• 108090000765 processed proteins & peptides Proteins 0.000 description 2
• 238000011084 recovery Methods 0.000 description 2
• 210000002345 respiratory system Anatomy 0.000 description 2
• 229960003471 retinol Drugs 0.000 description 2
• 235000020944 retinol Nutrition 0.000 description 2
• 239000011607 retinol Substances 0.000 description 2
• 230000037390 scarring Effects 0.000 description 2
• 238000012216 screening Methods 0.000 description 2
• 238000013207 serial dilution Methods 0.000 description 2
• 229940076279 serotonin Drugs 0.000 description 2
• 210000000419 skeletal muscle satellite cell Anatomy 0.000 description 2
• 210000004927 skin cell Anatomy 0.000 description 2
• 210000003625 skull Anatomy 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011780 sodium chloride Substances 0.000 description 2
• 239000000243 solution Substances 0.000 description 2
• 208000018198 spasticity Diseases 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 208000011580 syndromic disease Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 229940034208 thyroxine Drugs 0.000 description 2
• XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
• 230000009466 transformation Effects 0.000 description 2
• 230000008733 trauma Effects 0.000 description 2
• 238000011269 treatment regimen Methods 0.000 description 2
• 229940035722 triiodothyronine Drugs 0.000 description 2
• 231100000397 ulcer Toxicity 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 230000008673 vomiting Effects 0.000 description 2
• 238000005406 washing Methods 0.000 description 2
• 230000037303 wrinkles Effects 0.000 description 2
• CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
• PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
• 108010044267 Abnormal Hemoglobins Proteins 0.000 description 1
• 206010001541 Akinesia Diseases 0.000 description 1
• 102100026882 Alpha-synuclein Human genes 0.000 description 1
• KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 description 1
• 208000019838 Blood disease Diseases 0.000 description 1
• 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
• 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010006100 Bradykinesia Diseases 0.000 description 1
• 206010052346 Brain contusion Diseases 0.000 description 1
• 101100373139 Caenorhabditis elegans mig-14 gene Proteins 0.000 description 1
• 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 235000001258 Cinchona calisaya Nutrition 0.000 description 1
• 206010065163 Clonal evolution Diseases 0.000 description 1
• 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
• 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
• 206010010071 Coma Diseases 0.000 description 1
• 206010010904 Convulsion Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• 206010011971 Decreased interest Diseases 0.000 description 1
• FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
• 208000016192 Demyelinating disease Diseases 0.000 description 1
• 206010012305 Demyelination Diseases 0.000 description 1
• 206010012374 Depressed mood Diseases 0.000 description 1
• 208000020401 Depressive disease Diseases 0.000 description 1
• 241000208011 Digitalis Species 0.000 description 1
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
• 108010074604 Epoetin Alfa Proteins 0.000 description 1
• 206010015769 Extradural haematoma Diseases 0.000 description 1
• 206010016717 Fistula Diseases 0.000 description 1
• 206010016807 Fluid retention Diseases 0.000 description 1
• 108020004206 Gamma-glutamyltransferase Proteins 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
• 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
• 102000015779 HDL Lipoproteins Human genes 0.000 description 1
• 108010010234 HDL Lipoproteins Proteins 0.000 description 1
• 102100027685 Hemoglobin subunit alpha Human genes 0.000 description 1
• 108091005902 Hemoglobin subunit alpha Proteins 0.000 description 1
• 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
• 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
• 102100039894 Hemoglobin subunit delta Human genes 0.000 description 1
• 108091005903 Hemoglobin subunit delta Proteins 0.000 description 1
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
• 206010019663 Hepatic failure Diseases 0.000 description 1
• 206010019842 Hepatomegaly Diseases 0.000 description 1
• 208000011683 Hereditary muscle disease Diseases 0.000 description 1
• 101100182729 Homo sapiens LY6K gene Proteins 0.000 description 1
• 101000608228 Homo sapiens NLR family pyrin domain-containing protein 2B Proteins 0.000 description 1
• 101000849714 Homo sapiens Ribonuclease P protein subunit p29 Proteins 0.000 description 1
• 208000006083 Hypokinesia Diseases 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 108060003951 Immunoglobulin Proteins 0.000 description 1
• 206010062016 Immunosuppression Diseases 0.000 description 1
• 208000032578 Inherited retinal disease Diseases 0.000 description 1
• 206010022489 Insulin Resistance Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010074328 Interferon-gamma Proteins 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
• 206010061246 Intervertebral disc degeneration Diseases 0.000 description 1
• 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
• WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
• 208000034693 Laceration Diseases 0.000 description 1
• 241000713666 Lentivirus Species 0.000 description 1
• 206010024264 Lethargy Diseases 0.000 description 1
• 208000010415 Low Vision Diseases 0.000 description 1
• 102100032129 Lymphocyte antigen 6K Human genes 0.000 description 1
• 206010025323 Lymphomas Diseases 0.000 description 1
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 102000008934 Muscle Proteins Human genes 0.000 description 1
• 108010074084 Muscle Proteins Proteins 0.000 description 1
• 206010028293 Muscle contractions involuntary Diseases 0.000 description 1
• 208000029549 Muscle injury Diseases 0.000 description 1
• 208000021642 Muscular disease Diseases 0.000 description 1
• 201000009623 Myopathy Diseases 0.000 description 1
• 206010061533 Myotonia Diseases 0.000 description 1
• 208000010316 Myotonia congenita Diseases 0.000 description 1
• 206010068871 Myotonic dystrophy Diseases 0.000 description 1
• 102100039890 NLR family pyrin domain-containing protein 2B Human genes 0.000 description 1
• 206010060860 Neurological symptom Diseases 0.000 description 1
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
• 208000011623 Obstructive Lung disease Diseases 0.000 description 1
• 206010052181 Oculopharyngeal dystrophy Diseases 0.000 description 1
• 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 1
• 208000001388 Opportunistic Infections Diseases 0.000 description 1
• 102000016979 Other receptors Human genes 0.000 description 1
• 206010033661 Pancytopenia Diseases 0.000 description 1
• 206010033892 Paraplegia Diseases 0.000 description 1
• 206010035664 Pneumonia Diseases 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 206010064050 Polymenorrhagia Diseases 0.000 description 1
• 239000004793 Polystyrene Substances 0.000 description 1
• 102000003946 Prolactin Human genes 0.000 description 1
• 108010057464 Prolactin Proteins 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 208000011191 Pulmonary vascular disease Diseases 0.000 description 1
• 108700005075 Regulator Genes Proteins 0.000 description 1
• 206010057190 Respiratory tract infections Diseases 0.000 description 1
• 208000032430 Retinal dystrophy Diseases 0.000 description 1
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
• IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
• FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
• 208000018020 Sickle cell-beta-thalassemia disease syndrome Diseases 0.000 description 1
• 208000028979 Skull fracture Diseases 0.000 description 1
• 206010041660 Splenomegaly Diseases 0.000 description 1
• 208000002667 Subdural Hematoma Diseases 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 241001128391 Taia Species 0.000 description 1
• 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
• 102000004357 Transferases Human genes 0.000 description 1
• 108090000992 Transferases Proteins 0.000 description 1
• 206010060872 Transplant failure Diseases 0.000 description 1
• 206010052779 Transplant rejections Diseases 0.000 description 1
• GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
• 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
• 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
• 206010047513 Vision blurred Diseases 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• 229930003537 Vitamin B3 Natural products 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 206010000269 abscess Diseases 0.000 description 1
• 230000009102 absorption Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 201000006288 alpha thalassemia Diseases 0.000 description 1
• 108090000185 alpha-Synuclein Proteins 0.000 description 1
• 125000000539 amino acid group Chemical group 0.000 description 1
• 230000001494 anti-thymocyte effect Effects 0.000 description 1
• 230000002365 anti-tubercular Effects 0.000 description 1
• 239000000935 antidepressant agent Substances 0.000 description 1
• 229940005513 antidepressants Drugs 0.000 description 1
• 210000000612 antigen-presenting cell Anatomy 0.000 description 1
• 238000011225 antiretroviral therapy Methods 0.000 description 1
• 229940124522 antiretrovirals Drugs 0.000 description 1
• 239000003443 antiviral agent Substances 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 206010003246 arthritis Diseases 0.000 description 1
• 229940009098 aspartate Drugs 0.000 description 1
• 229960000794 baclofen Drugs 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 239000002876 beta blocker Substances 0.000 description 1
• 229940097320 beta blocking agent Drugs 0.000 description 1
• 230000008033 biological extinction Effects 0.000 description 1
• 210000002459 blastocyst Anatomy 0.000 description 1
• 230000036772 blood pressure Effects 0.000 description 1
• 238000009534 blood test Methods 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 230000037182 bone density Effects 0.000 description 1
• 229940112869 bone morphogenetic protein Drugs 0.000 description 1
• 230000009516 brain contusion Effects 0.000 description 1
• 230000006931 brain damage Effects 0.000 description 1
• 231100000874 brain damage Toxicity 0.000 description 1
• 208000029028 brain injury Diseases 0.000 description 1
• 210000000133 brain stem Anatomy 0.000 description 1
• 229940047036 calcium ascorbate Drugs 0.000 description 1
• 239000000969 carrier Substances 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 230000005779 cell damage Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 208000037887 cell injury Diseases 0.000 description 1
• 239000006285 cell suspension Substances 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 230000009920 chelation Effects 0.000 description 1
• 210000000038 chest Anatomy 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
• 238000011509 clonal analysis Methods 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000001447 compensatory effect Effects 0.000 description 1
• 230000009514 concussion Effects 0.000 description 1
• 230000001143 conditioned effect Effects 0.000 description 1
• 238000012790 confirmation Methods 0.000 description 1
• 208000028831 congenital heart disease Diseases 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000036461 convulsion Effects 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• 238000004163 cytometry Methods 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000002354 daily effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
• 208000006602 delta-Thalassemia Diseases 0.000 description 1
• 210000004443 dendritic cell Anatomy 0.000 description 1
• 238000000432 density-gradient centrifugation Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000000502 dialysis Methods 0.000 description 1
• 230000010339 dilation Effects 0.000 description 1
• 238000007865 diluting Methods 0.000 description 1
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• 239000002934 diuretic Substances 0.000 description 1
• 229940030606 diuretics Drugs 0.000 description 1
• 230000003291 dopaminomimetic effect Effects 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 230000004064 dysfunction Effects 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 201000010048 endomyocardial fibrosis Diseases 0.000 description 1
• 230000037149 energy metabolism Effects 0.000 description 1
• 229960003388 epoetin alfa Drugs 0.000 description 1
• 210000003013 erythroid precursor cell Anatomy 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 230000003203 everyday effect Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 238000009207 exercise therapy Methods 0.000 description 1
• 239000002360 explosive Substances 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000000646 extraembryonic cell Anatomy 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 235000019197 fats Nutrition 0.000 description 1
• 230000004720 fertilization Effects 0.000 description 1
• 230000004761 fibrosis Effects 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical group O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 238000007710 freezing Methods 0.000 description 1
• 230000008014 freezing Effects 0.000 description 1
• 238000002825 functional assay Methods 0.000 description 1
• 201000006321 fundus dystrophy Diseases 0.000 description 1
• 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
• 229940044627 gamma-interferon Drugs 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 238000001415 gene therapy Methods 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 230000002641 glycemic effect Effects 0.000 description 1
• 208000035474 group of disease Diseases 0.000 description 1
• 239000010440 gypsum Substances 0.000 description 1
• 229910052602 gypsum Inorganic materials 0.000 description 1
• 210000004326 gyrus cinguli Anatomy 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 208000018578 heart valve disease Diseases 0.000 description 1
• 210000002443 helper t lymphocyte Anatomy 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 210000000777 hematopoietic system Anatomy 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 229960002897 heparin Drugs 0.000 description 1
• 229920000669 heparin Polymers 0.000 description 1
• 230000003054 hormonal effect Effects 0.000 description 1
• 238000002657 hormone replacement therapy Methods 0.000 description 1
• 238000011577 humanized mouse model Methods 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 230000001096 hypoplastic effect Effects 0.000 description 1
• 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
• 230000008105 immune reaction Effects 0.000 description 1
• 230000036039 immunity Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 102000018358 immunoglobulin Human genes 0.000 description 1
• 238000003364 immunohistochemistry Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 229940121354 immunomodulator Drugs 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 230000002134 immunopathologic effect Effects 0.000 description 1
• 238000002650 immunosuppressive therapy Methods 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• 230000002458 infectious effect Effects 0.000 description 1
• 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 230000002608 insulinlike Effects 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 229940047122 interleukins Drugs 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 230000000366 juvenile effect Effects 0.000 description 1
• 230000002147 killing effect Effects 0.000 description 1
• 238000002372 labelling Methods 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 210000002414 leg Anatomy 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 229960004502 levodopa Drugs 0.000 description 1
• 239000006194 liquid suspension Substances 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000007903 liver failure Diseases 0.000 description 1
• 231100000835 liver failure Toxicity 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 238000011866 long-term treatment Methods 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 230000004303 low vision Effects 0.000 description 1
• 238000013123 lung function test Methods 0.000 description 1
• 206010025135 lupus erythematosus Diseases 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 238000005399 mechanical ventilation Methods 0.000 description 1
• 229940126601 medicinal product Drugs 0.000 description 1
• 210000003716 mesoderm Anatomy 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229960004584 methylprednisolone Drugs 0.000 description 1
• 229940029985 mineral supplement Drugs 0.000 description 1
• 235000020786 mineral supplement Nutrition 0.000 description 1
• 230000000394 mitotic effect Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 210000000214 mouth Anatomy 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 230000035772 mutation Effects 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 208000010125 myocardial infarction Diseases 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• 239000013642 negative control Substances 0.000 description 1
• 210000004126 nerve fiber Anatomy 0.000 description 1
• 210000000944 nerve tissue Anatomy 0.000 description 1
• 210000003061 neural cell Anatomy 0.000 description 1
• 210000001020 neural plate Anatomy 0.000 description 1
• 210000005155 neural progenitor cell Anatomy 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 210000005044 neurofilament Anatomy 0.000 description 1
• 230000004693 neuron damage Effects 0.000 description 1
• 230000000324 neuroprotective effect Effects 0.000 description 1
• 229960003512 nicotinic acid Drugs 0.000 description 1
• 229910052757 nitrogen Inorganic materials 0.000 description 1
• 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
• 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 1
• 238000010606 normalization Methods 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 108020004707 nucleic acids Proteins 0.000 description 1
• 102000039446 nucleic acids Human genes 0.000 description 1
• 150000007523 nucleic acids Chemical class 0.000 description 1
• 125000003835 nucleoside group Chemical group 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 210000004287 null lymphocyte Anatomy 0.000 description 1
• 201000005111 ocular hyperemia Diseases 0.000 description 1
• 210000004789 organ system Anatomy 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• 229940116315 oxalic acid Drugs 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000003836 peripheral circulation Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 239000008063 pharmaceutical solvent Substances 0.000 description 1
• 239000002953 phosphate buffered saline Substances 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 229920002223 polystyrene Polymers 0.000 description 1
• 238000009258 post-therapy Methods 0.000 description 1
• 229960002847 prasterone Drugs 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 239000000186 progesterone Substances 0.000 description 1
• 229960003387 progesterone Drugs 0.000 description 1
• 229940097325 prolactin Drugs 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 238000003133 propidium iodide exclusion Methods 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 238000001671 psychotherapy Methods 0.000 description 1
• 230000004088 pulmonary circulation Effects 0.000 description 1
• 229960000948 quinine Drugs 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 230000009103 reabsorption Effects 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 210000003019 respiratory muscle Anatomy 0.000 description 1
• 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
• 230000000452 restraining effect Effects 0.000 description 1
• 230000000717 retained effect Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 229960000329 ribavirin Drugs 0.000 description 1
• HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
• 229960004181 riluzole Drugs 0.000 description 1
• 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 238000007790 scraping Methods 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 229940001089 sinemet Drugs 0.000 description 1
• 210000001057 smooth muscle myoblast Anatomy 0.000 description 1
• 239000001540 sodium lactate Substances 0.000 description 1
• 229940005581 sodium lactate Drugs 0.000 description 1
• 235000011088 sodium lactate Nutrition 0.000 description 1
• 210000001082 somatic cell Anatomy 0.000 description 1
• 230000003595 spectral effect Effects 0.000 description 1
• 230000021595 spermatogenesis Effects 0.000 description 1
• 210000000952 spleen Anatomy 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 238000002660 stem cell treatment Methods 0.000 description 1
• 230000000638 stimulation Effects 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 210000003523 substantia nigra Anatomy 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 238000002636 symptomatic treatment Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 238000010257 thawing Methods 0.000 description 1
• 230000035922 thirst Effects 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 210000003437 trachea Anatomy 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000000472 traumatic effect Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 238000002604 ultrasonography Methods 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 208000019553 vascular disease Diseases 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 210000004515 ventral tegmental area Anatomy 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 235000019160 vitamin B3 Nutrition 0.000 description 1
• 239000011708 vitamin B3 Substances 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 235000019195 vitamin supplement Nutrition 0.000 description 1
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
• 230000003313 weakening effect Effects 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1
• 230000036642 wellbeing Effects 0.000 description 1